Similar articles

• A step forward for two-step screening for ovarian cancer.

  Hensley ML. Hensley ML. J Clin Oncol. 2010 May 1;28(13):2128-30. doi: 10.1200/JCO.2009.26.6346. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368556 No abstract available.
• Screening and detection of ovarian cancer.

  Breedlove G, Busenhart C. Breedlove G, et al. J Midwifery Womens Health. 2005 Jan-Feb;50(1):51-4. doi: 10.1016/j.jmwh.2004.10.002. J Midwifery Womens Health. 2005. PMID: 15637515 Review.
• Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

  Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ. Baron AT, et al. Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12582019
• Personalizing ovarian cancer screening.

  Goozner M. Goozner M. J Natl Cancer Inst. 2010 Aug 4;102(15):1112-3. doi: 10.1093/jnci/djq296. Epub 2010 Jul 28. J Natl Cancer Inst. 2010. PMID: 20668268 No abstract available.
• Proteins' promise--progress and challenges in ovarian cancer proteomics.

  Koehn H, Oehler MK. Koehn H, et al. Menopause Int. 2007 Dec;13(4):148-53. doi: 10.1258/175404507783004159. Menopause Int. 2007. PMID: 18088525 Review.